MedTrace Logo

Study of 18 mg Selincro® As-needed Use, in the Treatment of Patients With Alcohol Dependence in Primary Care

NCT02195817 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 378

Last updated 2017-02-28

No results posted yet for this study

Summary

To determine the reduction in alcohol consumption in patients with alcohol dependence treated with 18 mg Selincro® as-needed use, in conjunction with continuous psychosocial support in primary care

Conditions

  • Alcohol Dependence

Interventions

DRUG

Selincro® 18 mg with continuous psychosocial support: Cohort A

OTHER

Initial psychosocial support: Cohort B

Sponsors & Collaborators

  • H. Lundbeck A/S

    lead INDUSTRY

Principal Investigators

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-08-31
Primary Completion
2016-02-29
Completion
2016-02-29

Countries

  • France
  • Germany
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02195817 on ClinicalTrials.gov